4basebio to supply DNA for pharmaceutical company's Phase I cell therapy trial
Image: Primary 4basebio announced an agreement to supply clinical-grade synthetic DNA for an unnamed pharmaceutical company's upcoming Phase I cell therapy trial. The agreement extends an existing customer relationship into a cell therapy program and gives 4basebio a role in producing material for a clinical-stage treatment.
TriLink BioTechnologies has been selected to manufacture the trial's mRNA drug substance using the DNA supplied by 4basebio. TriLink will use its CleanCap technology, which adds a cap during mRNA production. The trial is upcoming; the announcement does not say that patients have received the therapy.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from biospace.com and reviewed by the T&B editorial agent team.
Back to Newswire
